Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protox Reports Positive Phase 2b BPH Results
Fahar Merchant, president and chief executive officer of Protox, said: “We are very excited about the results of the Triumph study. We believe that PRX302 has an immense
Fahar Merchant, president and chief executive officer of Protox, said: “We are very excited about the results of the Triumph study. We believe that PRX302 has an immense
The study is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, outpatient dose regimen-finding study. It will enroll approximately 200 patients who meet the criteria for RA with
The company claims that the new test is based on DNA methylation of the Septin9 gene, a biomarker associated with colorectal cancer that was identified by Epigenomics, a
The company claims that Dip and Read consists of biosensors and all the reagents required to quantitate Protein A or biosimilars such as MabSelect SuRe, in the presence
The company claims that Sidekick works alongside any Octet instrument and enables offline, simultaneous and uniform sample loading on all 96 biosensors on a biosensor tray. This increases
Built on the new Seeplex molecular diagnostic platform that delivers maximum specificity, reproducibility and sensitivity, the Canadian healthcare system can use the Seegene viral diarrhea detection kit to
The company said that with this acquisition, it becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings.
The company claims that OmniExpress designed as a 12-sample Beadchip, allows interrogation of over 700,000 variants per sample totaling more than eight million available data points on a
The company said that the technology is to be housed in Catalent’s Research Triangle Park, North Carolina facility, provides a flexible platform to reliably support all clinical manufacture
Fanapt belongs to a class of medications for schizophrenia known as atypical antipsychotics. The FDA approval of Fanapt was supported by two placebo-and active-controlled short-term trials and safety